Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.
|ISBN||1556-1380 (Electronic) 1556-0864 (Linking)|
|Authors||Barnet, M. B.; Zielinski, R. R.; Warby, A.; Lewis, C. R.; Kao, S.|
|Responsible Garvan Author|
|Publisher Name||Journal of Thoracic Oncology|
|Published Date||2018-01-01 00:00:00|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/28919393|